1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,434 | 0,462 | 04.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Do | IMMUNEONCO-B (01541): ANNOUNCEMENT PURSUANT TO RULES 14A.36, 14A.39 AND 14A.46 OF THE LISTING RULES | - | HKEx | ||
| 24.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.06. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT | 1 | HKEx | ||
| 16.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 08.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 2 | HKEx | ||
| 08.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | IMMUNEONCO-B (01541): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026 | 2 | HKEx | ||
| 22.05. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 19.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II RANDOMIZED AND PLACEBO-CONTROLLED TRIAL OF IMM0306 FOR THE TREATMENT ... | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2026 | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): NOTICE OF THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 ... | - | HKEx | ||
| 29.04. | IMMUNEONCO-B (01541): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 30.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY ... | - | HKEx | ||
| 25.03. | IMMUNEONCO-B (01541): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 13.03. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 06.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - (1) UNUSUAL PRICE MOVEMENTS; AND (2) APPROVAL OF IND APPLICATION OF IMM0306S (SUBCUTANEOUS FORMULATION) ... | - | HKEx | ||
| 10.02. | IMMUNEONCO-B (01541): CONNECTED TRANSACTION - THE LOAN AGREEMENT | 2 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,30 | -0,18 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| OCUGEN | 1,342 | -0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,550 | -0,31 % | Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying | ||
| INFLARX | 2,028 | -2,31 % | InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient... ► Artikel lesen | |
| EDITAS MEDICINE | 3,120 | -1,89 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,760 | -0,24 % | Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| BASILEA | 59,00 | +0,17 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,88 | +0,65 % | Chardan: Arrowhead Pharmaceuticals ist Top-Pick im Biotech-Sektor vor wichtigen Daten | ||
| TELIX PHARMACEUTICALS | 10,382 | +2,02 % | TELIX PHARMACEUTICALS LIMITED: Ceasing to be a substantial holder | ||
| TWIST BIOSCIENCE | 86,88 | -0,41 % | Cathie Wood's ARK sells Twist Bioscience, buys Circle Internet stock | ||
| ONCO-INNOVATIONS | 0,441 | -1,34 % | Onco-Innovations startet Programm zur Entwicklung und Charakterisierung des Polymerherstellungsprozesses für ONC010 | Vancouver, Kanada - 30. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, im Anschluss an... ► Artikel lesen | |
| REPLIGEN | 121,45 | -2,41 % | Repligen Corporation: Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26... ► Artikel lesen | |
| REVOLUTION MEDICINES | 168,25 | +0,72 % | +422% in einem Jahr: Revolution Medicines nach Bauchspeicheldrüsenkrebs-Durchbruch nicht zu ... | Die Rekordfahrt bei der Aktie von Revolution Medicines hat sich zu Wochenbeginn fortgesetzt. Erstmals in der Börsengeschichte der Biotech-Gesellschaft ist der Börsenwert auf über 40 Milliarden Dollar... ► Artikel lesen | |
| UNIQURE | 37,300 | +0,67 % | uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,98 % bei einem Aktienkurs von 0,414 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.